Alpha-1 antitrypsin deficiency: An under-recognized but important issue for respiratory therapists

Respiratory Care

Volumn 48, Issue 11, 2003, Pages 1022-1024

  Stoller, James K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT; RECOMBINANT PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CIGARETTE SMOKING; EDITORIAL; EMPHYSEMA; EVIDENCE BASED MEDICINE; GENETIC DISORDER; HEALTH CARE PERSONNEL; HUMAN; PATIENT CARE; RESPIRATORY CARE; RESPIRATORY THERAPIST; RISK FACTOR; ARTIFICIAL VENTILATION; ATTITUDE TO HEALTH; DISEASE COURSE; NOTE; PRACTICE GUIDELINE; PROFESSIONAL STANDARD;

ALPHA 1-ANTITRYPSIN DEFICIENCY; DISEASE PROGRESSION; EMPHYSEMA; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PRACTICE GUIDELINES; PROFESSIONAL ROLE; RESPIRATORY THERAPY;

EID: 1542648495     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
2. American Thoracic Society/European Repiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency: executive summary. Am J Respir Crit Care Med. 2003;168(7):820-822. Respir Care 2003 2003;48(11):1043-1047.
3. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha-1 antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994;61(6):461-467.
4. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158(1):49-59.
5. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, Ulrik CS, et al. A randomized clinical trial of alpha 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-1472.
6. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Eur Respir J 1997;10(10):2260-2263.
7. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001;119(3):737-744.
8. Minai OA, Stoller JK. Therapy for alpha 1-antitrypsin deficiency: pharmacology and clinical recommendations. BioDrugs 2000;13:135-147.
9. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 antitrypsin deficiency. Am J Med 1988;84(Suppl 6A):13-31.
10. Stoller JK. Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997;111(6 Suppl):123S-128S. Erratum in: Chest 1998 Feb;113(2):564.
11. Arroliga AC, Newman S, Longworth DL, Stoller JK. Metaphorical medicine: using metaphors to enhance communication with patients who have pulmonary disease. Ann Intern Med 2002;137(5 Pt 1):376-379.
12. O'Brien ML, Buist NRM, Murphey WH. Neonatal screening for alpha-1 antitrypsin deficiency. J Pediatr 1978;92(6):1006-1010.
13. Sveger T. Liver disease in alpha1- antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294(24):1316-1321.
14. Lieberman J, Winter B, Sastre A. Alpha1-antitrypsin Pi-types in 965 COPD patients. Chest 1986;89(3):370-373.
15. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States 1971-2000. MMWR 2002;51(SS06):1-16.
16. Rovner MS, Stoller JK. Therapy for alpha 1-antitrypsin deficiency: rationale and strategic approach. Clin Pulm Med 1994;1:135-143.